[Large cell neuroendocrine carcinoma of the nasopharynx: A case report].
Neuroendocrine carcinoma of the head and neck is a rare entity. The parotid gland is the most commonly affected site. A nasopharyngeal site has not been previously described. We report a 35-year-old patient who consulted for tinnitus and nasal obstruction. The assessment found a nasopharyngeal tumour T4N0M0. The patient underwent 6 cycles of chemotherapy based on VP16 and cisplatin, followed by radiotherapy at a dose of 70 Gy to the nasopharynx and 50 Gy to the neck. The evolution was marked by clinical improvement and radiological stability. Six months after the end of treatment, the patient had a local and meningeal relapse. He received palliative care. He died 19 months after the end of treatment.
Service de radiothérapie oncologique, CHU Habib Bourguiba, Sfax, Tunisie.
F
F
Elloumi
Service de radiothérapie oncologique, CHU Habib Bourguiba, Sfax, Tunisie. Electronic address: nejla_fourati@yahoo.fr.
N
N
Fourati
Service de radiothérapie oncologique, CHU Habib Bourguiba, Sfax, Tunisie.
W
W
Siala
Service de radiothérapie oncologique, CHU Habib Bourguiba, Sfax, Tunisie.
L
L
Ghorbell
Service de radiothérapie oncologique, CHU Habib Bourguiba, Sfax, Tunisie.
R
R
Jlidi
Service d'ORL, CHU Habib Bourguiba, Sfax, Tunisie.
A
A
Ghorbel
Service de carcinologie médicale, CHU Habib Bourguiba, Sfax, Tunisie.
M
M
Frikha
Service de radiothérapie oncologique, CHU Habib Bourguiba, Sfax, Tunisie.
J
J
Daoud
D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018287:Carcinoma, Large Cell / Q000473:pathology* / Q000556:secondary / Q000628:therapy; D018278:Carcinoma, Neuroendocrine / Q000473:pathology* / Q000556:secondary / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D017809:Fatal Outcome; D006801:Humans; D008297:Male; D008577:Meningeal Neoplasms / Q000556:secondary; D015508:Nasal Obstruction / Q000209:etiology; D009303:Nasopharyngeal Neoplasms / Q000473:pathology* / Q000628:therapy; D011879:Radiotherapy Dosage; D018714:Radiotherapy, Adjuvant; D014012:Tinnitus / Q000209:etiology
D000970:Antineoplastic Agents; D005047:Etoposide; D002945:Cisplatin
Cancer; Carcinoma; Carcinome neuroendocrine à grandes cellules; Large cell neuroendocrine carcinoma; Nasopharynx